TITLE

Review: Pioglitazone does not reduce risk for mortality or cardiovascular events in type 2 diabetes

PUB. DATE
March 2007
SOURCE
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p40
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study which states that pioglitazone does not reduce risk for mortality or cardiovascular events in type 2 diabetes. In the study, randomized controlled trials (RCTs) continued for 24 weeks that evaluated pioglitazone in adults with type 2 diabetes. Mortality and major morbidity events were reported by only 1 RCT that compared pioglitazone plus other glucose-lowering drugs with placebo plus other glucose-lowering drugs; mean follow-up was 35 months.
ACCESSION #
24685673

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics